Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease

April 2nd 2025

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Dr Morris on the FDA's Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mCRPC

April 2nd 2025

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Dr Dorff on the Safety of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC With Renal Impairment

April 1st 2025

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

The OncFive: Top Oncology Articles for the Week of 3/23

March 29th 2025

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

FDA Expands Indication for Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

March 28th 2025

The FDA has expanded the indication for lutetium Lu 177 vipivotide tetraxetan for use in additional patients with PSMA-positive metastatic castration-resistant prostate cancer.

Dr Morgans on PSA Doubling Time and Treatment Decisions in Biochemically Recurrent nmHSPC

March 25th 2025

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 3/16

March 22nd 2025

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Dr Bryce on the Comparative Efficacy of ARPIs Regardless of Disease Volume or Timing of Metastases in mHSPC

March 21st 2025

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

FDA Approves PSMA PET Imaging Agent TLX007-CDx for Prostate Cancer

March 20th 2025

The FDA has approved TLX007-CDx as an imaging agent in select patients with prostate cancer.

PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC

March 20th 2025

Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

March 13th 2025

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Ongoing Research to Watch in Prostate Cancer in 2025 and Beyond

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.

Key Prostate Cancer Updates to Emerge From ASCO GU 2025

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.

Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

March 13th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

The Evolution of Treatment in Metastatic Hormone-Sensitive Prostate Cancer

March 12th 2025

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

March 4th 2025

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.